Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × taletrectinib × 90 days × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 230 pembrolizumab 205 Magnetic Resonance Spectroscopy 188 Biopsy 141 Carboplatin 139 Cyclophosphamide 120 Nivolumab 113 Cisplatin 110 Paclitaxel 103 Radiotherapy 91 Gemcitabine 74 Bevacizumab 72 venetoclax 68 durvalumab 67 Dexamethasone 65 Oxaliplatin 60 Rituximab 58 Docetaxel 57 atezolizumab 56 Ipilimumab 56 Fluorouracil 56 Capecitabine 55 fludarabine 54 Prednisone 54 Etoposide 51 olaparib 49 Radiation 49 Drug Therapy 49 Doxorubicin 48 Cytarabine 48

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04919811 2026-01-07

TRUST-II

Nuvation Bio Inc.

Phase 2 Active not recruiting

217 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡